A disease that can blind and paralyze — and is often mistaken for MS
Neuromyelitis optica spectrum disorder, or NMOSD, is a rare autoimmune disease that attacks the optic nerves and spinal cord. Patients can lose vision, lose the ability to walk, or lose bladder control — sometimes all at once, during a single relapse.
It is often confused with multiple sclerosis (MS) because the symptoms look similar. But the underlying biology is different. In most NMOSD patients, the immune system produces a specific antibody — called AQP4-IgG — that attacks a water channel protein in the brain and spinal cord like a key jammed into the wrong lock.
The drug that's been doing the job — and its limits
Rituximab, a decades-old drug, has been used off-label to treat NMOSD by targeting a protein called CD20 on the surface of B cells (the immune cells that make the damaging antibody). It works reasonably well. But it has limitations, including the potential to cause the body to develop antibodies against the drug itself, which can reduce its effectiveness over time.
B001 was designed to do the same job — but better.
In lab studies before this trial, B001 showed stronger B cell depletion and better anti-proliferative effects compared to rituximab. That meant it killed more of the problematic B cells more efficiently.
B001 is what scientists call a recombinant humanized monoclonal antibody. That phrase sounds complex, but the core idea is simple: it's an engineered protein designed to attach to a specific target — CD20 — on B cells, and trigger those cells' destruction.
Think of B cells like soldiers producing the wrong orders. B001 works like a signal that marks those soldiers for removal before they can fire.
The "humanized" part matters. It means the antibody is built to resemble the body's own proteins closely enough that the immune system is less likely to attack it in return.
Who was in the trial and how it ran
This phase 1b trial enrolled 22 adults with confirmed NMOSD — specifically the type positive for the AQP4-IgG antibody. Patients received intravenous infusions of B001 at one of three doses (350 mg, 700 mg, or 1,000 mg) or a placebo, with dosing on day 1 and again on day 15. Researchers then followed participants for 24 weeks.
No dose-limiting toxicity occurred — meaning the drug did not cause serious enough harm at any tested dose to stop the trial. Side effects were generally mild. About a third of treated patients experienced some treatment-related side effects, most commonly urinary tract infections or mild infusion reactions. None required stopping the drug.
Importantly, B cell counts dropped to nearly zero within the first few weeks and stayed suppressed for the entire 24-week observation window. Zero NMOSD relapses occurred during the study period.
No relapses in 24 weeks is a meaningful signal — but this trial was too small and too short to treat it as a definitive result.
Where this fits in the field
NMOSD management has improved significantly in recent years with the approval of several targeted therapies. But access to these treatments varies widely by country, and cost can be prohibitive. B001, if it continues through trials successfully, could offer another option — potentially with different dosing or cost profiles than what's currently available.
The 700 mg dose was selected as the recommended dose for the next phase of testing based on how the drug behaved at different concentrations in the body.
If you or someone you care about has NMOSD, this trial is a reason for cautious hope — not a reason to seek out this drug now. B001 is not approved and is not available outside of clinical trials.
Talk to a neurologist who specializes in NMOSD about whether any open trials may be appropriate for your situation.
The limits of this study
Twenty-two patients is a very small number. The trial was not designed to prove the drug works — only to show it is safe enough to test further. The 24-week window is also short for a disease that can go months or years between relapses, which makes interpreting the relapse rate difficult.
What comes next
A phase 2 trial is now being planned using the 700 mg dose. That trial will be larger, longer, and designed to measure whether B001 actually prevents relapses better than existing therapies. If the results are strong, phase 3 trials and eventual regulatory review could follow — a process that typically takes several more years.
